No Data
Amgen Inc. (AMGN): Hedge Funds Are Bullish on This Blue Chip Dividend Stock Now
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $375
Jefferies analyst Michael Yee maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $375.According to TipRanks data, the analyst has a success rate of 44.0% and a total
Beat the Market Like Zacks: Carvana, Adobe, Amgen in Focus
Ideaya Stock Jumps After Positive Study Data From Cancer Study
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.